Learn More
Powering A New Era Of mRNA Therapeutics
Opus aims to unlock existing limitations within the drug delivery space by enabling safer mRNA chronic re-dose / single dose therapeutics.
the problem
LNPs are one of the most promising delivery modalities, but their inherent Toxicity has led to failed trials and clinical setbacks. Other delivery modalities face tradeoffs in cargo, safety, efficacy, and single-dose / chronic re-dosing therapies.
Our Technology
A New Gold Standard
- 01
Most LNPs use cationic ionizable lipids, which trigger immune-activating pathways. Opus has created a new class of LNPs that bypass these immune pathways, enabling safe, repeat-dose / single-dose therapies without compromising mRNA expression.
- 02
Opus LNPs enable treatment of both chronic re-dosing protein replacement therapies and single-dose gene editing therapies—areas currently limited by immunogenicity.
- 03
Opus aims to enable not only intravenous (IV) administration of its LNPs, but also more patient-friendly routes such as subcutaneous (SC) injection.
Our story
A New Approach To Non-Viral Delivery
Opus was founded out of the Murthy Lab at the Innovative Genomics Institute, UC Berkeley. Our team of scientists specializes in developing novel drug delivery systems, with a focus on advancing mRNA therapeutics.
